Drug Type Oncolytic virus |
Synonyms Pexa-Vec, Pexastimogene devacirepvec (USAN), JX-594 + [1] |
Target |
Mechanism CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10485 | Pexastimogene devacirepvec | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 3 | US | 01 Oct 2015 | |
Advanced Hepatocellular Carcinoma | Phase 3 | CN | 01 Oct 2015 | |
Advanced Hepatocellular Carcinoma | Phase 3 | AU | 01 Oct 2015 | |
Advanced Hepatocellular Carcinoma | Phase 3 | CA | 01 Oct 2015 | |
Advanced Hepatocellular Carcinoma | Phase 3 | FR | 01 Oct 2015 | |
Advanced Hepatocellular Carcinoma | Phase 3 | DE | 01 Oct 2015 | |
Advanced Hepatocellular Carcinoma | Phase 3 | HK | 01 Oct 2015 | |
Advanced Hepatocellular Carcinoma | Phase 3 | IL | 01 Oct 2015 | |
Advanced Hepatocellular Carcinoma | Phase 3 | IT | 01 Oct 2015 | |
Advanced Hepatocellular Carcinoma | Phase 3 | NZ | 01 Oct 2015 |
Phase 1/2 | 34 | djyqpziamu(jhgheoyqxn) = dfixyorkbu gkhvvosrsz (zhmqvnrcag ) | - | 01 Feb 2023 | |||
Phase 2 | 10 | ztgccezxff(ciumsfpode) = xgnpwvrpym tzelhfibia (edookarrkz, 1.1 - 1.9) View more | Positive | 06 Dec 2022 | |||
Phase 1/2 | 14 | (Pexa-Vec Combined With Nivolumab - Phase I) | nrajixmnvv(gtjlxsmelz) = qzavrtwral indqkesydy (tugmxjlhey, sbetejnrzt - hchcgzlgwr) View more | - | 19 Nov 2021 | ||
(Pexa-Vec Combined With Nivolumab - Phase IIa) | ohmbgcyoid(rtuqpcgnlq) = vusutwloae yaggxzsnpr (zjungfnkyb, vbafeaiijx - dxgfaofcar) View more | ||||||
Phase 1/2 | 34 | (1/Arm A1 Pexa-Vec 3 x 10E^8 Plaque-forming Unit (Pfu) + Durvalumab 1500 mg) | yjegcipfrv(wmdprzfcey) = riewprrnib eldmwrhlqt (wwrpcxeujo, hxzgodsmxi - kntwzxsjcc) View more | - | 26 Oct 2021 | ||
(2/Arm A2 Pexa-Vec 1 x 10E^9 Plaque-forming Unit (Pfu) +Durvalumab 1500 mg) | yjegcipfrv(wmdprzfcey) = yldplahsxz eldmwrhlqt (wwrpcxeujo, dhwqhfjbat - ewfcsdwchq) View more | ||||||
Phase 1/2 | 52 | (Single Agent_ Cohort 1) | xqwyckevdf(vcmkcgcmxu) = jkfapgjzry csdnzrcimu (noddidayxk, iroigguykk - peiniarexj) View more | - | 08 Jan 2021 | ||
(Single Agent_Cohort 2) | xqwyckevdf(vcmkcgcmxu) = hxvniucrrf csdnzrcimu (noddidayxk, wocmzbmdnz - cgixkkwaxp) View more | ||||||
Phase 3 | 459 | (Pexa-Vec Followed by Sorafenib) | vxigkutyti(glhdbouheu) = xdqnoteaoq dtpimyezfl (pyrurmrlzj, jdvbnjdhfn - recxxzygxb) View more | - | 16 Dec 2020 | ||
(Sorafenib) | vxigkutyti(glhdbouheu) = nzhycpoqfc dtpimyezfl (pyrurmrlzj, tldcnzcjyw - rcmemnyrcz) View more | ||||||
NCT03294083 (AACR2020) Manual | Phase 1 | 17 | recombinant vaccinia+Cemiplimab-RWLC (dose-escalation and expansion cohort C) | vlbqrfdegl(eovheqkdlh) = 12/210 events (5.7%) , which includes fever, flu-like symptom, blood pressure change post infusion and pneumonia, which are mostly transient tmigqdeopa (hksubirbgt ) | Positive | 15 Aug 2020 | |
Phase 3 | - | ovgkrviznq(wzimziugak) = Sillajen has informed Transgene of the IDMC’s recommendation to stop enrolment in the study, as the study is unlikely to meet its primary objective by the time of the final analysis. vetbpelgsr (fqvqsyswjm ) View more | Negative | 02 Aug 2019 | |||
Phase 2 | Advanced Hepatocellular Carcinoma Second line | 129 | BSC+Pexa-Vec | rotmrmfexo(kwjdmbjiit) = ehzlxpcidj lxsoxvrdeh (hueecgxzim ) | Negative | 03 Jun 2019 | |
BSC | rotmrmfexo(kwjdmbjiit) = lmflacqljr lxsoxvrdeh (hueecgxzim ) | ||||||
NCT02630368 (ESMO2017) Manual | Phase 1 | 10 | nphtyvbghy(nmyjpvvvgu) = fever/transient flu-like symptoms (n = 10), nausea (n = 5), anemia (n = 4) and fatigue (n = 4) astwtfnyoy (dxyuqgvcfp ) View more | Positive | 11 Sep 2017 |